deferiprone has been researched along with daunorubicin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Adamcová, M; Gersl, V; Guncová, I; Hroch, M; Mazurová, Y; Popelová, O; Simůnek, T; Sterba, M | 1 |
2 other study(ies) available for deferiprone and daunorubicin
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Cardiotonic Agents; Cell Proliferation; Daunorubicin; Deferiprone; Heart Diseases; HL-60 Cells; Humans; Male; Pyridones; Rabbits | 2008 |